BOULDER, Colorado and SAN FRANCISCO, June 4, 2021 (GLOBE NEWSWIRE) — Biodesix, a leading company in lung cancer diagnostic solutions, announced a strategic partnership with Datavant, the leader in helping healthcare organizations securely connect their data. Datavant provides solutions to help protect, match and share health data. Through this partnership, Biodesix will anonymize the lung cancer portion of their extensive sample and data biobank using Datavant’s proprietary tokenization process and connect it to multiple real-world data sets, while protecting patient privacy compliantly and securely. Given the high need for robustly curated real-world evidence (RWE) linked to outcomes, claims data, comprehensive standard of care data and biomarkers, Biodesix plans to make its database and linked data accessible to their research and biopharmaceutical partners. Not only does patient-level data help clinicians improve treatment decisions, it also informs researchers and biopharmaceutical companies about key decisions during the product development cycle, from early discovery to late-stage clinical development, including applications as meaningful synthetic RWE control arms.
The lung cancer-specific portion of Biodesix’ 150,000 samples and data and biobank includes both baseline and longitudinal samples with proteomic and genomic lab results. Part of the database includes treatment decisions and outcome data for patients enrolled in the company’s ongoing INSIGHT study (NCT03289780). This unique observational study includes non-small cell lung cancer (NSCLC) patients at all stages and histologies drawing blood at baseline and serially at progression. The dataset will record treatment plan, clinical features and will track triennial outcomes for all NSCLC patients from 33 academic and community clinics. By linking this data to other data sets, the partnership will provide a more complete longitudinal picture of patient health, while protecting patient privacy.
🎬📺 Free Movies and Free TV Shows! 🎭🎬
“In our collaboration with our research and biopharmaceutical partners, they are constantly looking for datasets that reflect the real world,” said Dr. Paul Beresford, Chief Business Officer of Biodesix. “With our database and biospecimen repository now linked to the Datavant ecosystem, we can help our partners answer a range of clinical, reimbursement and biomarker questions in lung cancer. In particular, our partners will benefit from the comprehensive information to help discover biomarker-driven targeted therapies. We also expect the data to be used for clinically relevant synthetic control arms to help design and conduct clinical trials that will ultimately broaden patients’ access to life-changing drugs. We look forward to improving our dataset and increasing the value we bring to our biopharmaceutical partners through our partnership with Datavant.”
“We are excited to partner with Biodesix to make faster and more informed decisions, improving patient quality of life and care,” said Travis May, Founder and Chief Executive Officer of Datavant. “We believe that connecting the rich Biodesix data with other sources of real-world data will advance lung cancer diagnosis, treatment and research.”
Datavant’s mission is to connect the world’s health data to improve outcomes for patients. Datavant is working to reduce the friction of data sharing in healthcare by building technology that protects patient privacy while supporting the linking of unidentified patient records between data sets. Datavant is headquartered in San Francisco. Read more about Datavant on www.datavant.com.
Biodesix is a leading diagnostic company with a focus on lung disease. The company develops diagnostic tests that answer important clinical questions by combining multi-omics with the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with lung disease. Biodesix launched the Bio-Rad SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and the virus affecting the lungs and causing COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, accelerating treatment time. The blood-based Nodify Lung® nodule risk assessment strategy, consisting of the Nodify XL2® and Nodify CDT™ tests, evaluates the risk of malignancy in incidental lung nodules, allowing physicians to better direct patients to the most appropriate course of action. Biodesix also partners with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit: biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve significant risks and uncertainties for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements in this press release, except statements of historical fact, are forward-looking statements. The words ‘believe’, ‘can’, ‘will’, ‘estimate’, ‘continue’, ‘anticipate’, ‘plan’, ‘plan’, ‘expect’, ‘forecast’, ‘potential’, ‘opportunity’ ‘, “purposes” or “should” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements due to many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may contain information about the impact of the COVID-19 pandemic on Biodesix and its business, possible or assumed future results of operations, including descriptions of its revenue, profitability, prospects and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’ most recent Annual Report on Form 10K, filed March 16, 2021. Biodesix assumes no obligation to the results of any revision of such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Elenee Argentinis, Head of Marketing
🎬📺 Free Movies and Free TV Shows! 🎭🎬